Accepted at: Sep, 30, 2025 7:36 a.m.
Author: braviboron
Related Deck: 1675118865074
Accepted
Rationale for new note

Child naloxone

Text
Text
What is the pharmacological management of <b>opioid overdose </b>in <u>a child</u>?<br><br>{{c1::Naloxone 10&nbsp;micrograms/kg (maximum 400&nbsp;micrograms), repeated as necessary to a total of 2&nbsp;mg}}
Extra
Extra
Therapeutic Guidlines recommend 0.01 mg to 0.2 mg, this card follows AMH
Extra (Synced)
Empty field
Extra (Synced)
Personal Notes
Empty field
Personal Notes
Missed Questions
Empty field
Missed Questions
eTG Complete
eTG Complete
<img src="8c5e386c79125d2bac9f2dc293819013.webp">
Talley & O'Connor
Empty field
Talley & O'Connor
Additional Resources
Additional Resources
<div class="figure-header" style="font-size:12px;"><b>AMH:</b></div><b><img src="61c7e080a227e56fa9cf5aacc2dba9e4.webp"></b><br>
Additional Resources (Synced)
Empty field
Additional Resources (Synced)
Source
Source
<ul><li>AMH: Naloxone&nbsp;<a href="https://amhonline-amh-net-au.eu1.proxy.openathens.net/chapters/antidotes-antivenoms/antidotes/naloxone">https://amhonline-amh-net-au.eu1.proxy.openathens.net/chapters/antidotes-antivenoms/antidotes/naloxone</a>&nbsp;last modified July 2024. Accessed 15 December 2024</li><li>eTG - Opioid poisoning: general management <a href="https://app-tg-org-au.ap1.proxy.openathens.net/viewTopic?etgAccess=true&amp;guidelinePage=Toxicology%20and%20Toxinology&amp;topicfile=what-is-covered-in-toxicology-toxinology&amp;guidelinename=auto§ionId=c_opioid_poisoning#c_opioid_poisoning">https://app-tg-org-au.ap1.proxy.openathens.net/viewTopic?etgAccess=true&amp;guidelinePage=Toxicology and Toxinology&amp;topicfile=what-is-covered-in-toxicology-toxinology&amp;guidelinename=auto&amp;sectionId=c_opioid_poisoning#c_opioid_poisoning</a> Published/Amended July 2024, Accessed 19 August 2025</li></ul>
One by one
Empty field
One by one
Tags
#Malleus_CM::#eTG_Complete::Toxicology_and_Toxinology::Opioid_poisoning::Opioid_poisoning:_general_management #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Buprenorphine::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Codeine::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Fentanyl::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Hydromorphone::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Methadone::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Morphine::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Oxycodone::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Pethidine::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Tepentadol::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::03_Analgesics::01_Drugs_for_pain_relief::02_Opioid_analgesics::Tramadol::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::05_Antidotes_and_antivenoms::02_Antidotes::Naloxone::03_Indications #Malleus_CM::#Pharmacology::18_Psychotropic_drugs::08_Drugs_for_opioid_dependence::Buprenorphine::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::18_Psychotropic_drugs::08_Drugs_for_opioid_dependence::Methadone::07_Toxicity_&_Reversal #Malleus_CM::#Pharmacology::19_Respiratory_drugs::02_Drugs_for_cough::01_Opioid_cough_suppresants::Codeine::07_Toxicity_&_Reversal #Malleus_CM::#Question_Banks::eMedici::2000-2999::2589 #Malleus_CM::#Question_Banks::eMedici::2000-2999::2648 #Malleus_CM::#Resources_by_Rotation::Anaesthetics #Malleus_CM::#Resources_by_Rotation::Emergency #Malleus_CM::#Subjects::Emergency_Medicine::02_Toxicology::01_Drug_Poisonings::Opiate_Overdose::10_Management #Malleus_CM::#Subjects::Psychiatry::10_Drug-Related_Disorders::02_Substance_Use_Disorders::Opioids